Athersys (NASDAQ:ATHX) versus Revelation Biosciences (NASDAQ:REVB) Head to Head Contrast

Revelation Biosciences (NASDAQ:REVB) and Athersys (NASDAQ:ATHX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation.

Risk and Volatility

Revelation Biosciences has a beta of 0.18, indicating that its share price is 82% less volatile than the S&P 500. Comparatively, Athersys has a beta of -0.9, indicating that its share price is 190% less volatile than the S&P 500.

Insider & Institutional Ownership

12.8% of Revelation Biosciences shares are owned by institutional investors. Comparatively, 19.4% of Athersys shares are owned by institutional investors. 0.2% of Revelation Biosciences shares are owned by company insiders. Comparatively, 0.0% of Athersys shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings for Revelation Biosciences and Athersys, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revelation Biosciences	0	0	0	0	N/A
Athersys	0	0	0	0	N/A

Profitability

This table compares Revelation Biosciences and Athersys’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Revelation Biosciences	N/A	-152.41%	-74.43%
Athersys	N/A	N/A	-223.03%

Earnings and Valuation

This table compares Revelation Biosciences and Athersys”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revelation Biosciences	N/A	N/A	-$120,000.00	($28.53)	-0.03
Athersys	$146,000.00	0.00	-$72.53 million	($2.03)	N/A

Revelation Biosciences has higher earnings, but lower revenue than Athersys. Revelation Biosciences is trading at a lower price-to-earnings ratio than Athersys, indicating that it is currently the more affordable of the two stocks.

About Revelation Biosciences

Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California.

About Athersys

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. The company was founded in 1995 and is headquartered in Cleveland, Ohio.